| |
Lux Biosciences to Present at BIO CEO & Investor Conference 2008
JERSEY
CITY, N.J., February 4, 2008--
Lux Biosciences,
Inc., a privately held biotechnology company specialized in the field of
ophthalmic diseases, announced today that Ulrich
Grau, President and CEO, will present a company overview at the BIO CEO &
Investor Conference 2008 on Monday, February 11, 2008, at 2:00 PM ET at The
Waldorf=Astoria Hotel in New York City.
The presentation will be
webcast live and may be accessed at
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=**LUX&item_id=1756133.
An archived version of the webcast will be available at the same location
for 30 days following the presentation.
About Lux Biosciences
Lux Biosciences, Inc. is
a privately held biotechnology company focused on ophthalmic diseases. The
company has a staged product portfolio of potentially first-in-class
therapies distinguished by their short-term path to commercialization and
potential to generate high revenue growth. The portfolio includes:
-
Two Phase III
clinical-stage projects including: i) LX211, the oral formulation of a
next-generation calcineurin inhibitor developed as steroid sparing
therapy for the treatment of non-infectious uveitis, and ii) LX201, a
silicone matrix ocular (episcleral) implant that steadily releases
therapeutic doses of cyclosporine A locally to the eye for the
prevention of rejection cornea transplant recipients. Both the LUMINATE
pivotal clinical program for LX211 for the treatment of uveitis, as well
as the LUCIDA pivotal clinical program with LX201 for the prevention of
corneal transplant rejection were initiated in early 2007 and include
sites in North America and Europe.
-
LX214, a novel
topical eye drop formulation currently in IND-enabling studies with a
target date for entry into the clinic in mid 2008. LX214 is based on
Lux’s proprietary next-generation calcineurin inhibitor and is targeted
towards other chronic inflammatory diseases of the eye, most notably dry
eye syndrome, blepharitis and atopic keratoconjunctivitis.
-
Several earlier
stage projects based on proprietary product-enabling bio-erodible
polymer technologies that facilitate targeted and sustained delivery of
molecules to the eye.
For
more information on Lux Biosciences, please visit the company’s website at
www.luxbio.com.
###
CONTACTS:
Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201 946 0221
Ulrich.grau@luxbio.com
Kureczka/Martin Associates (media)
Joan Kureczka
+1 415-821-2413
Jkureczka@comcast.net
|
